PL445439A1 - Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem - Google Patents

Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem

Info

Publication number
PL445439A1
PL445439A1 PL445439A PL44543923A PL445439A1 PL 445439 A1 PL445439 A1 PL 445439A1 PL 445439 A PL445439 A PL 445439A PL 44543923 A PL44543923 A PL 44543923A PL 445439 A1 PL445439 A1 PL 445439A1
Authority
PL
Poland
Prior art keywords
cov
sars
diagnosis
prevention
epitopes
Prior art date
Application number
PL445439A
Other languages
English (en)
Inventor
Sabina GÓRSKA
Agnieszka RAZIM
Beata ORZECHOWSKA
Andrzej Gamian
Original Assignee
Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu filed Critical Instytut Immunologii I Terapii Doświadczalnej Im.Ludwika Hirszfelda Pan We Wrocławiu
Priority to PL445439A priority Critical patent/PL445439A1/pl
Priority to PCT/PL2024/050047 priority patent/WO2025005816A1/en
Publication of PL445439A1 publication Critical patent/PL445439A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)

Abstract

Przedmiotem wynalazku są nowe peptydy pochodzące z białek koronawirusa SARS-CoV-2, będące immunoreaktywnymi epitopami oddziałowującymi z surowicą ozdrowieńców ich zastosowanie w prewencji i diagnostyce zakażeń wirusem SARS-CoV-2 oraz nowatorska szczepionka przeciwko wirusowi SARS-CoV-2, zawierająca immunoreaktywne peptydy oraz termostabilny nanoadiuwant umożliwiający efektywne podanie donosowe.
PL445439A 2023-06-30 2023-06-30 Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem PL445439A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL445439A PL445439A1 (pl) 2023-06-30 2023-06-30 Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem
PCT/PL2024/050047 WO2025005816A1 (en) 2023-06-30 2024-07-01 Sars-cov-2 protein epitopes and use thereof in prevention and diagnosis of coronavirus infections

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL445439A PL445439A1 (pl) 2023-06-30 2023-06-30 Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem

Publications (1)

Publication Number Publication Date
PL445439A1 true PL445439A1 (pl) 2025-01-07

Family

ID=93939535

Family Applications (1)

Application Number Title Priority Date Filing Date
PL445439A PL445439A1 (pl) 2023-06-30 2023-06-30 Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem

Country Status (2)

Country Link
PL (1) PL445439A1 (pl)
WO (1) WO2025005816A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021223647A1 (en) * 2020-05-06 2021-11-11 The University Of Hong Kong Compositions and methods for making and using vaccines against covid-19
WO2022061248A2 (en) * 2020-09-18 2022-03-24 Wisconsin Alumni Research Foundation Identification of sars-cov-2 epitopes discriminating covid-19 infection from control and methods of use
CN114605506A (zh) * 2022-04-08 2022-06-10 湖南大学 冠状病毒m蛋白胞外域多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113666990B (zh) * 2021-08-24 2024-09-17 复旦大学 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021223647A1 (en) * 2020-05-06 2021-11-11 The University Of Hong Kong Compositions and methods for making and using vaccines against covid-19
WO2022061248A2 (en) * 2020-09-18 2022-03-24 Wisconsin Alumni Research Foundation Identification of sars-cov-2 epitopes discriminating covid-19 infection from control and methods of use
CN114605506A (zh) * 2022-04-08 2022-06-10 湖南大学 冠状病毒m蛋白胞外域多肽及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BAO-ZHONG ZHANG AT AL.: "bioRxiv 2020.04.23.056853", MAPPING THE IMMUNODOMINANCE LANDSCAPE OF SARS-COV-2 SPIKE PROTEIN FOR THE DESIGN OF VACCINES AGAINST COVID-19. *
C.M. POH ET AL.: "Nature Communications 2020; 11(1):2806", TWO LINEAR EPITOPES ON THE SARS-COV-2 SPIKE PROTEIN THAT ELICIT NEUTRALISING ANTIBODIES IN COVID-19 PATIENTS. *

Also Published As

Publication number Publication date
WO2025005816A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
BR112021020957A2 (pt) Capsídeos de vírus adenoassociado (aav) variante para liberação intravítrea
MXPA05009580A (es) Vacuna contra el virus de la influenza.
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
BRPI0107679B8 (pt) composição compreendendo vesículas de membrana externa do grupo sérico b de neisseria meningitidis e um componente inorgânico e uso da mesma
JP2017501986A5 (ja) 二重特異性ｈｉｖ−１中和抗体
MX2022013963A (es) Composiciones de virus adenoasociados compatibles entre especies y metodos de uso de las mismas.
Halbherr et al. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus
Cao et al. A single vaccine protects against SARS-CoV-2 and influenza virus in mice
EA201171032A1 (ru) Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами
EA201000829A1 (ru) Вакцина
ZA202107428B (en) Porcine circovirus type 3 (pcv3) vaccines, and production and uses thereof
BR0214188A (pt) Anticorpos monoclonais contra vìrus da hepatite e ou seus fragmentos com atividade de ligação e uso dos mesmos
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
WO2022010938A3 (en) Catalysis deactivated angiotensin-converting enzyme 2 (ace2) variants and their uses
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
Aparicio et al. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses
MX2022015489A (es) Vacuna de virus vaccinia modificado de ankara (mva) recombinante contra la enfermedad del coronavirus.
ATE507286T1 (de) Immunisierung von fischen gegen virusinfektion
PL445439A1 (pl) Epitopy białek wirusa SARS-CoV-2 i ich zastosowanie w prewencji i diagnostyce zakażeń koronawirusem
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
WO2006071896A3 (en) Epitope-based sars vaccine
PH12020551944A1 (en) Reverse peptide vaccine